Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sunder Mudaliar

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Diabetologia|July 5, 2019
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?David M Nathan, Peter H Bennett, Jill P Crandall, et al.
Circulation|February 12, 2024
Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)Jennifer B Green, Brendan M Everett, Alokananda Ghosh, et al.
Journal of the American College of Cardiology|September 1, 2004
Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitusMeenakshi A Bhalla, Audrey Chiang, Victoria A Epshteyn, et al.
BMC Endocrine Disorders|July 31, 2009
Actos Now for the prevention of diabetes (ACT NOW) studyRalph A Defronzo, Maryann Banerji, George A Bray, et al.
JAMA Internal Medicine|May 22, 2023
Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical TrialDeborah J Wexler, Ian H de Boer, Alokananda Ghosh, et al.
The Journal of Clinical Endocrinology and Metabolism|March 17, 2016
Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOWDevjit Tripathy, Dawn C Schwenke, MaryAnn Banerji, et al.
Diabetes Care|April 8, 2014
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOWDevjit Tripathy, Stephen C Clement, Dawn C Schwenke, et al.
Diabetes|July 19, 2013
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlatesRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Diabetes|August 5, 2009
Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosisPeter D Reaven, Thomas E Moritz, Dawn C Schwenke, et al.
Diabetes Care|September 25, 2013
Prediction of diabetes based on baseline metabolic characteristics in individuals at high riskRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Diabetologia|July 5, 2019
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?David M Nathan, Peter H Bennett, Jill P Crandall, et al.
Circulation|February 12, 2024
Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)Jennifer B Green, Brendan M Everett, Alokananda Ghosh, et al.
Journal of the American College of Cardiology|September 1, 2004
Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitusMeenakshi A Bhalla, Audrey Chiang, Victoria A Epshteyn, et al.
BMC Endocrine Disorders|July 31, 2009
Actos Now for the prevention of diabetes (ACT NOW) studyRalph A Defronzo, Maryann Banerji, George A Bray, et al.
JAMA Internal Medicine|May 22, 2023
Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical TrialDeborah J Wexler, Ian H de Boer, Alokananda Ghosh, et al.
The Journal of Clinical Endocrinology and Metabolism|March 17, 2016
Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOWDevjit Tripathy, Dawn C Schwenke, MaryAnn Banerji, et al.
Diabetes Care|April 8, 2014
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOWDevjit Tripathy, Stephen C Clement, Dawn C Schwenke, et al.
Diabetes|July 19, 2013
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlatesRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Diabetes|August 5, 2009
Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosisPeter D Reaven, Thomas E Moritz, Dawn C Schwenke, et al.
Diabetes Care|September 25, 2013
Prediction of diabetes based on baseline metabolic characteristics in individuals at high riskRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Pageof 9